ClinicalTrials.gg
RecruitingNCT05929859iChainUpdated Jan 13, 2026

Intensive Speech Motor Chaining Treatment for Residual Speech Sound Disorders

A Phase 1/2 interventional study of Speech Motor Chaining in Speech Sound Disorder, sponsored by Syracuse University. Recruiting at 1 site in United States. Open to participants aged 9 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Syracuse University · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years later.
Phase
Phase 1/2
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
9 Years to 17 Years
Sex
All
01

Study summary

The goal of this randomized-controlled trial is to compare distributed treatment schedules and intensive treatment schedules in 84 school-age children with residual speech sound disorders. The main question it aims to answer is:

  • How does intensive and distributed treatment affect speech sound learning in residual speech sound disorder?

Some participants will be treated with a traditional Distributed schedule of 2 sessions per weeks for 8 weeks (16 hours total), whereas others will be treated with an Intensive schedule and will complete 16 hours of treatment in 4 weeks.

Read the detailed description

Residual speech sound disorders are defined as speech sound disorders that persist past \~8-9 years and may lead to social, academic, and vocational limitations. Thus, there is a need to investigate how treatment schedules affect speech sound learning. The overall objective of this study is to optimize a suite of theoretically motivated, high-fidelity, motor-based treatments delivered at the appropriate intensity, despite practical barriers, for the most commonly impacted RSSD sounds: /ɹ, s/. Our central working hypothesis, supported by our preliminary work, is that Speech Motor Chaining is more efficacious when delivered intensively (i.e., closely spaced for a fixed number of sessions). The theoretical rationale is that increasing intensity early in treatment will mitigate erred practice between sessions, improving outcomes relative to more customary practice distributions. To test this hypothesis, children will be randomly assigned to receive a standard Distributed treatment schedule or an Intensive treatment schedule.

02

Conditions studied

  • Speech Sound Disorder

Browse trials for

03

In context

Speech Sound Disorder

46 studies on the registry are indexed under Speech Sound Disorder; 16 are open to participants now.

This study's planned enrollment of 84 is above the median of 40 across 39 interventional studies indexed under Speech Sound Disorder.

Browse Speech Sound Disorder studies →

Lead sponsor

Syracuse University is the lead sponsor of 33 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
9 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must speak American English as a dominant language.
  • Must have began learning English by at least the age of 3 years.
  • Must be between 9;0 to 17;11 years of age.
  • Must have reported difficulty with /ɹ/ and/or /s/ production
  • Must pass pure tone hearing screening at 25 dB at 1000, 2000, and 4000 Hz.
  • Must receive a scaled score of at least 5 on the Listening Comprehension and Story Retelling subtests of the Test of Integrated Language and Literacy Skills (TILLS)
  • Must receive a percentile score of 5 or below on the Goldman-Fristoe Test of Articulation-3 (GFTA-3) Sounds in Words subtest.
  • Must have 1 scorable response with 5+ consecutive correct /pataka/ with > 3.4 syllables per second in the MRR-Tri task of the Maximum Performance Tasks OR must demonstrate no childhood apraxia of speech (CAS-only) features in BOTH articulatory and rate/prosody domains of the ProCAD.
  • Must score \<40% accurate on /ɹ/ and/or /s/ probes assessing these sounds at the word level.
  • Must express a desire to modify their speech.

Exclusion criteria

Exclusion Criteria:

  • Must have no known history of autism spectrum disorder, Down Syndrome, cerebral palsy, intellectual disability, permanent hearing loss, or brain injury.
  • Must not have current cleft palate or voice disorder.
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Intensive Treatment

    Speech Motor Chaining will be delivered in an intensive fashion. Week 1: 8 sessions (2 sessions per day on 4 different days) Week 2: 3 sessions (1 per day on 3 different days) Week 3: 3 sessions (1 per day on 3 different days) Week 4: 2 sessions (1 per day on 2 different days)

    Behavioral: Speech Motor Chaining

  • Experimental
    Distributed Treatment

    Speech Motor Chaining will be delivered twice weekly for 8 weeks

    Behavioral: Speech Motor Chaining

Interventions

  • BehavioralSpeech Motor Chaining

    Sessions begin with Pre-practice to elicit target sounds, with verbal cueing and shaping strategies. During Structured Practice, items are practice in blocks of 6 consecutive trials (with systematic increases in difficulty), and our web-based software will manipulate the principles of motor learning, including the stimulus prompt, the participant's production, analysis of the clinician's rating, feedback prompts for the clinician, and the variability present in the practice trial. Randomized Practice will also be guided by the software and includes all linguistic levels that were produced correctly during Structured Practice, with items presented in random order.

06

What researchers measure

Primary outcomes

  1. Change in percent correct for treated sound, rated by blinded listeners.

    To assess generalization of treatment gains to untreated words, participants will read a 200-word probe list eliciting the treated sound (/ɹ/ or /s/). Stimuli in each probe will be presented individually in randomized order. No auditory models will be provided; for children with reading difficulty, semantic cues will be provided to elicit the intended word. Individual words will be isolated from the audio record of each word probe and presented in randomized order for binary rating (correct/incorrect) by listeners who are blind to treatment condition and time point (but will see the written representation of each target word). We will use the change in percent correct as our primary measure of perceptually rated accuracy.

    Time frame: Before the initiation of treatment and again 10 weeks later.

Secondary outcomes

  1. Proportion of responders and non-responders in each group.

    A chi-square test will be used to analyze the proportion of responders and non-responders (i.e., those above/below 15% change on the probes) in each group.

    Time frame: 10 weeks after the start of treatment.

  2. Survey evaluating impacts of speech disorder on participants' social, emotional, and academic well-being.

    This survey asks parents and participants to report the impact of speech disorder on their child's/their social, emotional, and academic well-being. Parents and participants are asked to select a number from 1 to 5 (1 = Strongly disagree, 3 = Neutral, 5 = Strongly agree). For all questions, a higher score indicates a greater degree of negative impact of speech disorder on social, emotional, or academic well-being.

    Time frame: Before the initiation of treatment and again 10 weeks later.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Preston JL, Leece MC, Storto J. Tutorial: Speech Motor Chaining Treatment for School-Age Children With Speech Sound Disorders. Lang Speech Hear Serv Sch. 2019 Jul 12;50(3):343-355. doi: 10.1044/2018_LSHSS-18-0081. Epub 2019 May 3. PubMed 31051085 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05929859
Lead sponsor
Syracuse University
Responsible party
Sponsor
First posted
Jul 3, 2023
Start date
Oct 26, 2023
Primary completion
Feb 29, 2028 (estimated)
Completion
Feb 29, 2028 (estimated)
Last update
Jan 13, 2026

Study contacts

Jonathan Preston, PhD
Contact
jopresto@syr.edu
315-443-1351
Nina Benway, PhD
Contact
nrbenway@syr.edu
Jonathan Preston, PhD
principal investigator · Syracuse University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion